Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Sponsor: MacroGenics
This PHASE2/PHASE3 trial investigates Gastric Cancer and Gastroesophageal Junction Cancer and is currently completed. MacroGenics leads this study, which shows 27 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
27 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
May 2025 — Jul 2025 [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
▶ Show 22 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Oct 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2021 — Nov 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MacroGenics
- Zai Lab (Shanghai) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .